[en] BACKGROUND: Relapse after treatment of Hodgkin's disease (HD) is usually identified as a result of the investigation of symptoms. We undertook this study to examine the value of whole-body positron emission tomography (PET) for the detection of preclinical relapse. PATIENTS AND METHODS: Thirty-six patients underwent 2-[fluorine-18]fluoro-2-deoxy-D-glucose ((18)F-FDG) PET at the end of treatment and than every 4-6 months for 2-3 years after the end of polychemotherapy and/or radiotherapy. In those cases of abnormal (18)F-FDG accumulation a confirmatory study was performed 4-6 weeks later. RESULTS: One patient had residual tumor and four patients relapsed during a follow-up of 5-24 months. All five events were correctly identified early by (18)F-FDG PET. Residual tumor or relapse was never first diagnosed based on clinical examination, laboratory findings or computed tomography (CT) studies. Two patients presented B symptoms and the three others were asymptomatic at the time of residual disease or relapse. Confirmation of residual disease or relapse was obtained by biopsy in four patients 1, 1, 5 and 9 months after PET and by unequivocal clinical symptoms and CT studies in one patient 3 months after PET. False-positive (18)F-FDG PET studies incorrectly suggested possible relapse in six other patients, but the confirmatory PET was always negative. Our study also provides important information about physiological (18)F-FDG uptake in the thymus. CONCLUSIONS: Our data suggest the potential of (18)F-FDG PET to detect preclinical relapse in patients with HD. This could help identify patients requiring salvage chemotherapy at the time of minimal disease rather than at the time of clinically overt relapse. Further studies are warranted to determine the impact of PET on treatment management and outcome. In fact, the aim of follow-up procedures is not only to detect preclinical relapse but mainly to obtain better results by starting salvage treatment earlier. A cost-benefit analysis will also be necessary before (18)F-FDG PET can be used routinely in the follow-up of patients with HD.
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fassotte, Marie-France ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Belhocine, T.
Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
Rigo, Pierre ; Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
Rigo P, Paulus P, Kaschten BJ et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma. with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116.
Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
Bangerter M, Moog F, Buchmann I et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-1122.
Weidmann E, Baican B, Hertel A et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymph 1999; 34: 545-551.
Partridge S, Timothy AR, O'Doherty MJ. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatement staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.
Hueltenschmidt B, Sautter-Bihl ML, Lang O et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302-310.
Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
Romer W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
Jerusalem G, Beguin Y, Fassotte MF et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618.
Cremerius U, Fabry U, Neuerburg J et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 1055-1063.
Jerusalem G, Beguin Y, Fassotte ME et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181-1184.
Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11 (Suppl 1): S147-S150.
Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
de Wit M, Bohuslavizki KH, Buchert R et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
Spaepen K, Stroobants S, Dupont P et al. Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-278.
Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. Br Med J 1997; 314: 343-346.
Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997; 15: 1123-1130.
Khan A, Herman PG, Jojas KA et al. Comparison of CT and chest radiographs in the evaluation of post-therapy lymphoma patients. Eur J Radiol 1989; 9: 96-100.
Rahmouni A, Divine M, Lavaud A et al. Role of X-ray computed tomography in the follow-up of the course of Hodgkin's disease. French J Radiol 1993; 74: 99-103. [In French].
Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
Weeks JC, Yeap BY, Canellos GP et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9: 1196-1203.
Friedman S, Henry-Amar M, Cosset JM et al. Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease. J Clin Oncol 1988; 6: 596-602.
Front D, Bar-Shalom R, Epelbaum R et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med 1993; 34: 2101-2104.
Jerusalem G, Beguin Y. Commentary on 'Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography'. Clin Lymphoma 2000; 1: 75-76.
Cohen M, Hill CA, Cangir A, Sullivan MP. Thymic rebound after treatment of childhood tumors. Am J Roentgenol 1980; 135: 151-156.
Peylan-Ramu N, Haddy TB, Jones E et al. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 1989; 7: 1800-1806.
Patel PM, Alibazoglu H, Ali A et al. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21: 772-775.
Weinblatt ME, Zanzi I, Belakhlef A et al. False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997; 38: 888-890.